-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Larimar Therapeutics, Raises Price Target to $13

Benzinga·03/20/2026 12:28:41
Listen to the news
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and raises the price target from $12 to $13.